Evidence map›Paper›PMID 29491307›Full record

ArticleInternal medicine (Tokyo, Japan)2018

An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.

Masami Miki, Ken Kawabe, Hisato Igarashi, Tatsuro Abe, Yoshihiro Ohishi, Risa Hashimoto, Takashi Karashima, Ichiro Yamasaki, Keiji Inoue, Tetsuhide Ito and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Masami MikiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Ken KawabeDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Hisato IgarashiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Tatsuro AbeDepartment of Anatomic Pathology Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Yoshihiro OhishiDepartment of Anatomic Pathology Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Risa HashimotoDepartment of Gastroenterology, Saiseikai Fukuoka General Hospital, Japan.
Takashi KarashimaDepartment of Urology, Kochi Medical School, Kochi University, Japan.
Ichiro YamasakiDepartment of Urology, Kochi Medical School, Kochi University, Japan.
Keiji InoueDepartment of Urology, Kochi Medical School, Kochi University, Japan.
Tetsuhide ItoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Yoshihiro OgawaDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Kyushu University · JPKōchi University · JPSaiseikai Fukuoka General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first- and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

Indexed as

Antineoplastic AgentsAsian PeopleCarcinoma, NeuroendocrineEverolimusFemaleHumansIndolesLiver NeoplasmsMiddle AgedPancreatic NeoplasmsPyrrolesSunitinibTreatment Outcomevon Hippel-Lindau DiseaseAntineoplastic AgentsEverolimusIndolesPyrrolesSunitinibeverolimuspancreatic neuroendocrine tumors-G3 (NET-G3)von Hippel-Lindau disease (VHL)well-differentiated neuroendocrine carcinoma (WDNEC)WHO G3

Identifiers

PMID29491307
PMCPMC6096011
OpenAlexW2790135528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.